Proprietary AI analyst is now available
- Public Comps
- Sangamo Therapeutics
Sangamo Therapeutics Valuation Multiples
Discover Sangamo Therapeutics' revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Annovis Bio, Rein Therapeutics, Heron Therapeutics, Dongkoo Bio&Pharma Co and more.
Sangamo Therapeutics Overview
About Sangamo Therapeutics
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington’s Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
Founded
1995
HQ

Employees
183
Website
Financials (LTM)
EV
$66M
Valuation Multiples
Start free trialSangamo Therapeutics Financials
Sangamo Therapeutics reported last 12-month revenue of $40M and negative EBITDA of ($112M).
In the same LTM period, Sangamo Therapeutics generated $39M in gross profit, ($112M) in EBITDA losses, and had net loss of ($114M).
Revenue (LTM)
Sangamo Therapeutics P&L
In the most recent fiscal year, Sangamo Therapeutics reported revenue of $40M and EBITDA of ($100M).
Sangamo Therapeutics is unprofitable as of last fiscal year, with EBITDA margin of (254%) and net margin of (311%).
Financial data powered by Morningstar, Inc.
Sangamo Therapeutics Stock Performance
Sangamo Therapeutics has current market cap of $74M, and enterprise value of $66M.
Market Cap Evolution
Sangamo Therapeutics' stock price is $0.18.
Sangamo Therapeutics share price decreased by 67.0% in the last year.
Sangamo Therapeutics has an EPS (earnings per share) of $-0.30.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $66M | $74M | 5.0% | - | -27.7% | -67.0% | $-0.30 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSangamo Therapeutics Valuation Multiples
Sangamo Therapeutics trades at 1.6x EV/Revenue multiple, and (0.6x) EV/EBITDA.
EV / Revenue (LTM)
Sangamo Therapeutics Financial Valuation Multiples
As of June 18, 2026, Sangamo Therapeutics has market cap of $74M and EV of $66M.
Sangamo Therapeutics has a P/E ratio of (0.6x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Sangamo Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Sangamo Therapeutics Margins & Growth Rates
Sangamo Therapeutics grew revenue by 3% and EBITDA by 5% in the last fiscal year.
In the most recent fiscal year, Sangamo Therapeutics reported EBITDA margin of (254%) and net margin of (311%).
Sangamo Therapeutics Margins
Sangamo Therapeutics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Sangamo Therapeutics Operational KPIs
Sangamo Therapeutics' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.8M for the same period.
Sangamo Therapeutics' Rule of 40 is (256%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sangamo Therapeutics' Rule of X is (252%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Sangamo Therapeutics Competitors
Sangamo Therapeutics competitors include Annovis Bio, Rein Therapeutics, Heron Therapeutics, Dongkoo Bio&Pharma Co, Pliant Therapeutics, Replek, Adicet Bio, XBiotech, Gain Therapeutics and Lytix Biopharma.
Most Sangamo Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | - | (2.0x) | (1.2x) | |||
| - | - | (3.4x) | - | |||
| 1.1x | 1.1x | 11.6x | 11.6x | |||
| 0.8x | - | 2.7x | - | |||
| - | - | 0.5x | 0.6x | |||
| 2.2x | - | 11.1x | - | |||
| - | - | 0.4x | - | |||
| - | - | 2.1x | - | |||
This data is available for Pro users. Sign up to see all Sangamo Therapeutics competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Sangamo Therapeutics
Sangamo Therapeutics has acquired 1 company to date.
Last acquisition by Sangamo Therapeutics was on July 23rd 2018. Sangamo Therapeutics acquired TxCell for $78M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Sangamo Therapeutics
| Description | TxCell is a Sophia Antipolis-based biopharma company developing Tr1 cell therapies for autoimmune diseases including Crohn's and rheumatoid arthritis. The ENTRALLY platform targets refractory patients, with Phase II trials completed in Europe showing 50% response rates. Spun out from Inserm in 2007, TxCell collaborates with Takeda and operates GMP facilities in France. |
| HQ Country | |
| HQ City | Nice |
| Deal Date | 23 Jul 2018 |
| Valuation | $78M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Sangamo Therapeutics acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Sangamo Therapeutics
| When was Sangamo Therapeutics founded? | Sangamo Therapeutics was founded in 1995. |
| Where is Sangamo Therapeutics headquartered? | Sangamo Therapeutics is headquartered in United States. |
| How many employees does Sangamo Therapeutics have? | As of today, Sangamo Therapeutics has over 183 employees. |
| Who is the CEO of Sangamo Therapeutics? | Sangamo Therapeutics' CEO is Alexander Donald Macrae. |
| Is Sangamo Therapeutics publicly listed? | Yes, Sangamo Therapeutics is a public company listed on OTCM. |
| What is the stock symbol of Sangamo Therapeutics? | Sangamo Therapeutics trades under SGMO ticker. |
| When did Sangamo Therapeutics go public? | Sangamo Therapeutics went public in 2000. |
| Who are competitors of Sangamo Therapeutics? | Sangamo Therapeutics main competitors include Annovis Bio, Rein Therapeutics, Heron Therapeutics, Dongkoo Bio&Pharma Co, Pliant Therapeutics, Replek, Adicet Bio, XBiotech, Gain Therapeutics, Lytix Biopharma. |
| What is the current market cap of Sangamo Therapeutics? | Sangamo Therapeutics' current market cap is $74M. |
| What is the current revenue of Sangamo Therapeutics? | Sangamo Therapeutics' last 12 months revenue is $40M. |
| What is the current revenue growth of Sangamo Therapeutics? | Sangamo Therapeutics revenue growth (NTM/LTM) is 104%. |
| What is the current EV/Revenue multiple of Sangamo Therapeutics? | Current revenue multiple of Sangamo Therapeutics is 1.6x. |
| Is Sangamo Therapeutics profitable? | No, Sangamo Therapeutics is not profitable. |
| What is the current EBITDA of Sangamo Therapeutics? | Sangamo Therapeutics has negative EBITDA and is not profitable. |
| What is Sangamo Therapeutics' EBITDA margin? | Sangamo Therapeutics' last 12 months EBITDA margin is (279%). |
| What is the current EV/EBITDA multiple of Sangamo Therapeutics? | Current EBITDA multiple of Sangamo Therapeutics is (0.6x). |
| How many companies Sangamo Therapeutics has acquired to date? | As of June 2026, Sangamo Therapeutics has acquired 1 company. |
| What was the largest acquisition by Sangamo Therapeutics? | $78M acquisition of TxCell on 23rd July 2018 was the largest M&A Sangamo Therapeutics has done to date. |
| What companies Sangamo Therapeutics acquired? | Sangamo Therapeutics acquired TxCell. |
| In how many companies Sangamo Therapeutics has invested to date? | Sangamo Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Sangamo Therapeutics
Lists including Sangamo Therapeutics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
